|
Status |
Public on Mar 02, 2018 |
Title |
vehicle treated MCF-7/c-Jun +Tet cells, biological rep1 |
Sample type |
RNA |
|
|
Source name |
MCF-7/c-Jun +Tet cells
|
Organism |
Homo sapiens |
Characteristics |
treatment: vehicle
|
Treatment protocol |
Cells were cultured in steroid depleted media for 72 h and treated with ethnaol, 10 nM 17β-estradiol or 1μM Tamoxifen for 24 h.
|
Growth protocol |
MCF-7/c-Jun +Tet cells were maintained in DMEM supplemented with 10% FBS containing media in presence of 2μg/ml tetracycline.MCF-7/c-Jun -Tet cells were maintained in 10% FBS containing media in absence of tetracycline.
|
Extracted molecule |
total RNA |
Extraction protocol |
Total RNA was extracted using RNeasy Mini Kit (Qiagen, Valencia, CA).
|
Label |
biotin
|
Label protocol |
Total RNA was converted to sense strand cDNA using Ambion WT Expression kit. For fragmentation and labeling WT GeneChip WT target Labeling kit was used.
|
|
|
Hybridization protocol |
Hybridization to Clariom™ D Assay_ human array catridge was carried out overnight with biotin-labeled cRNA according to the Affymetrix protocol.
|
Scan protocol |
Array plates were scanned using a GeneTitan scanner.
|
Description |
Gene expression data using ethanol as vehicle control
|
Data processing |
Preprocessing in Affymetrix Transcriptome Analysis Console (TAC) Software (v. 3.1) using the following methods: Summarization: PLIER, Background Correction: PM-GCBG, Normalization: Global Median.
|
|
|
Submission date |
Aug 08, 2017 |
Last update date |
Mar 02, 2018 |
Contact name |
Karin Dahlman-Wright |
Organization name |
Karolinska Institutet
|
Department |
Department of Biosciences and Nutrition
|
Lab |
Medicinaren 25/Neo
|
Street address |
Blickagången 16
|
City |
Huddinge |
ZIP/Postal code |
14157 |
Country |
Sweden |
|
|
Platform ID |
GPL23126 |
Series (2) |
GSE102367 |
c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer [expression profiling] |
GSE102412 |
ERα and AP-1 coordinate transcription and tamoxifen response in ERα-positive breast cancer |
|